Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 2/2017

01-02-2017

Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics

Authors: Chrisanna Dobrowolski, Edward G. Clark, Manish M. Sood

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2017

Login to get access

Abstract

The worldwide prevalence of chronic kidney disease is 10–15 % of the adult population, is rising and increases susceptibility to venous thromboembolism (VTE). In this narrative review we discuss the underlying evidence behind the association of VTE/CKD and examine the role of worsening CKD stage, proteinuria, and the risk of recurrent VTE. As CKD may alter therapeutic options we discuss the role of emerging therapies, the non-vitamin K oral anticoagulants (NOAC), in the treatment of VTE.
Literature
1.
Arora P, Vasa P, Brenner D et al (2013) Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 185:E417–E423CrossRefPubMedPubMedCentral
2.
Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J (2015) International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol 2015:184321CrossRefPubMedPubMedCentral
3.
4.
Ng AC, Chung T, Yong AS et al (2011) Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 4:122–128CrossRefPubMed
5.
6.
Keller C, Katz R, Cushman M, Fried LF, Shlipak M (2008) Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 9:9CrossRefPubMedPubMedCentral
7.
Shlipak MG, Fried LF, Crump C et al (2003) Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87–92CrossRefPubMed
8.
Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K (2014) Haemostasis in chronic kidney disease. Nephrol Dial Transplant 29:29–40CrossRefPubMed
9.
Al-Massarani G, Vacher-Coponat H, Paul P et al (2009) Kidney transplantation decreases the level and procoagulant activity of circulating microparticles. Am J Transplant 9:550–557CrossRefPubMed
10.
Camaioni C, Gustapane M, Cialdella P, Della Bona R, Biasucci LM (2013) Microparticles and microRNAs: new players in the complex field of coagulation. Intern Emerg Med 8:291–296CrossRefPubMed
11.
Statistics NCfH (2014) Survey results and products from the National Health and Nutrition Examination Survey. In: Centers for Disease Control and Prevention (ed) Hyattsville
12.
Centers for Disease Control and Prevention (2014) Chronic kidney disease surveillance system—United States
13.
14.
Christiansen CF, Schmidt M, Lamberg AL et al (2014) Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost 12:1449–1454CrossRefPubMed
15.
16.
Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619CrossRefPubMed
17.
Kato S, Chernyavsky S, Tokita JE et al (2010) Relationship between proteinuria and venous thromboembolism. J Thromb Thrombolysis 30:281–285CrossRefPubMed
18.
Grams ME, Plantinga LC, Hedgeman E et al (2011) Validation of CKD and related conditions in existing data sets: a systematic review. Am J Kidney Dis 57:44–54CrossRefPubMed
19.
Vlasschaert ME, Bejaimal SA, Hackam DG et al (2011) Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis 57:29–43CrossRefPubMed
20.
Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR (2008) Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 19:135–140CrossRefPubMedPubMedCentral
21.
Folsom AR, Lutsey PL, Astor BC et al (2010) Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant 25:3296–3301CrossRefPubMedPubMedCentral
22.
Königsbrügge O, Lötsch F, Zielinski C, Pabinger I, Ay C (2014) Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res 134:44–49CrossRefPubMed
23.
Brodin EE, Brækkan SK, Vik A, Brox J, Hansen JB (2012) Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function–the Tromsø study. Haematologica 97:1008–1013CrossRefPubMedPubMedCentral
24.
Shlipak MG, Matsushita K, Ärnlöv J et al (2013) Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369:932–943CrossRefPubMedPubMedCentral
25.
Grubb A, Horio M, Hansson LO et al (2014) Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. Clin Chem 60:974–986CrossRefPubMed
26.
27.
Mahmoodi BK, Gansevoort RT, Veeger NJ et al (2009) Microalbuminuria and risk of venous thromboembolism. JAMA 301:1790–1797CrossRefPubMed
28.
van Schouwenburg IM, Mahmoodi BK, Veeger NJ, Kluin-Nelemans HC, Gansevoort RT, Meijer K (2012) Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol 156:667–671CrossRefPubMed
29.
American College of Chest Physicians (2012) Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e691S–736SCrossRef
30.
31.
32.
Thrombosis Canada (2015) Clinical guides: venous thromboembolism
33.
34.
Connolly SJ, Milling TJ, Eikelboom JW et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016
35.
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352CrossRefPubMed
36.
Schulman S, Kearon C, Kakkar AK et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709–718CrossRefPubMed
37.
Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510CrossRefPubMed
38.
Büller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRefPubMed
39.
Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808CrossRefPubMed
40.
Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMed
41.
Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMed
42.
Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMed
Metadata
Title
Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics
Authors
Chrisanna Dobrowolski
Edward G. Clark
Manish M. Sood
Publication date
01-02-2017
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1437-1

Other articles of this Issue 2/2017

Journal of Thrombosis and Thrombolysis 2/2017 Go to the issue

OriginalPaper

Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants

OriginalPaper

Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study

Letter to the Editor

Continuation of direct oral anticoagulants in the acute phase of ischemic stroke. A case series

OriginalPaper

Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant

OriginalPaper

A novel mutation in exon 2 of FGB caused by c.221G>T † substitution, predicting the replacement of the native Arginine at position 74 with a Leucine (p.Arg74Leu † ) in a proband from a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis

OriginalPaper

Estimation of right ventricular dysfunction by computed tomography pulmonary angiography: a valuable adjunct for evaluating the severity of acute pulmonary embolism
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits